ID   DG-75
AC   CVCL_0244
SY   D.G.-75; DG 75; DG75
DR   BTO; BTO:0003637
DR   CLO; CLO_0002767
DR   EFO; EFO_0002160
DR   MCCL; MCC:0000134
DR   CLDB; cl1051
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2625
DR   BioSample; SAMN03471755
DR   BioSample; SAMN03473403
DR   cancercelllines; CVCL_0244
DR   Cell_Model_Passport; SIDM00948
DR   CGH-DB; 9196-4
DR   ChEMBL-Cells; CHEMBL3308527
DR   ChEMBL-Targets; CHEMBL2366199
DR   Cosmic; 906838
DR   Cosmic; 931103
DR   Cosmic; 1086327
DR   Cosmic; 1118471
DR   Cosmic; 1191698
DR   Cosmic; 1588563
DR   Cosmic-CLP; 906838
DR   DepMap; ACH-002232
DR   DSMZCellDive; ACC-83
DR   EGA; EGAS00001000978
DR   GDSC; 906838
DR   GEO; GSM710428
DR   GEO; GSM710444
DR   GEO; GSM827239
DR   GEO; GSM1669731
DR   IARC_TP53; 8094
DR   IGRhCellID; DG75
DR   NCBI_Iran; C495
DR   PharmacoDB; DG75_290_2019
DR   PRIDE; PXD004181
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0244
DR   PubChem_Cell_line; CVCL_0244
DR   TOKU-E; 3578
DR   Wikidata; Q54831039
RX   PubMed=188769;
RX   PubMed=2985879;
RX   PubMed=3037521;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=8558920;
RX   PubMed=8896424;
RX   PubMed=9473234;
RX   PubMed=9525742;
RX   PubMed=9583678;
RX   PubMed=9685479;
RX   PubMed=9770427;
RX   PubMed=11425244;
RX   PubMed=12706092;
RX   PubMed=17254797;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=24590883;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Jewish; Ashkenazi.
CC   Virology: EBV-negative.
CC   Virology: Infected by DG-75 retrovirus, a replication-competent, murine leukemia-related retrovirus. Constitutively produces the virus.
CC   Doubling time: 18-20 hours (PubMed=188769); ~40-50 hours (DSMZ=ACC-83).
CC   HLA typing: A*02,11; B*39,41 (PubMed=3037521).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=9583678; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Homozygous (PubMed=9583678).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283His (c.848G>A); ClinVar=VCV000142324; Zygosity=Heterozygous (PubMed=9525742).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.72%; Native American=1.16%; East Asian, North=0%; East Asian, South=1.7%; South Asian=7.84%; European, North=25.56%; European, South=62.01% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CRL-2625; Cosmic-CLP=906838; DSMZ=ACC-83; PubMed=17254797
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10,11,12 (DSMZ=ACC-83)
ST   CSF1PO: 10 (PubMed=17254797)
ST   CSF1PO: 10,11,12 (ATCC=CRL-2625; Cosmic-CLP=906838)
ST   D13S317: 9,11 (PubMed=17254797)
ST   D13S317: 10,11 (DSMZ=ACC-83)
ST   D13S317: 11 (ATCC=CRL-2625; Cosmic-CLP=906838)
ST   D16S539: 11 (PubMed=17254797)
ST   D16S539: 11,12 (Cosmic-CLP=906838)
ST   D16S539: 11,12,13 (DSMZ=ACC-83)
ST   D16S539: 12 (ATCC=CRL-2625)
ST   D18S51: 11,13 (PubMed=17254797)
ST   D18S51: 11,14,15,16 (ATCC=CRL-2625; DSMZ=ACC-83)
ST   D19S433: 12,13
ST   D21S11: 27,30 (PubMed=17254797)
ST   D21S11: 29,31.2 (ATCC=CRL-2625; DSMZ=ACC-83)
ST   D2S1338: 17,23 (ATCC=CRL-2625)
ST   D2S1338: 17,22,23 (DSMZ=ACC-83)
ST   D3S1358: 15,16,17 (ATCC=CRL-2625; DSMZ=ACC-83)
ST   D3S1358: 16,17 (PubMed=17254797)
ST   D5S818: 12
ST   D7S820: 11,12 (PubMed=17254797)
ST   D7S820: 11.3,12 (DSMZ=ACC-83)
ST   D7S820: 11.3,12,12.3 (ATCC=CRL-2625)
ST   D7S820: 12 (Cosmic-CLP=906838)
ST   D8S1179: 13,15 (ATCC=CRL-2625; PubMed=17254797)
ST   D8S1179: 14,15 (DSMZ=ACC-83)
ST   FGA: 20,21,22,23,24 (DSMZ=ACC-83)
ST   FGA: 20,21,23 (ATCC=CRL-2625)
ST   FGA: 20,23 (PubMed=17254797)
ST   Penta D: 12,13
ST   Penta E: 6,7,17,19 (ATCC=CRL-2625)
ST   Penta E: 7,16,17 (DSMZ=ACC-83)
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,17,18,19 (DSMZ=ACC-83)
ST   vWA: 17,18 (ATCC=CRL-2625; PubMed=17254797)
ST   vWA: 17,18,19 (Cosmic-CLP=906838)
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   10Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 40
RX   PubMed=188769; DOI=10.1002/ijc.2910190105;
RA   Ben-Bassat H., Goldblum N., Mitrani-Rosenbaum S., Goldblum T.,
RA   Yoffey J.M., Cohen M.M., Bentwich Z., Ramot B., Klein E., Klein G.;
RT   "Establishment in continuous culture of a new type of lymphocyte from
RT   a 'Burkitt like' malignant lymphoma (line D.G.-75).";
RL   Int. J. Cancer 19:27-33(1977).
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
RX   PubMed=3037521; DOI=10.1073/pnas.84.13.4567;
RA   Masucci M.G., Torsteinsdottir S., Colombani J., Brautbar C., Klein E.,
RA   Klein G.;
RT   "Down-regulation of class I HLA antigens and of the Epstein-Barr
RT   virus-encoded latent membrane protein in Burkitt lymphoma lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4567-4571(1987).
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C.";
RL   Leuk. Res. 9:549-559(1985).
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
RX   PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562;
RA   Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.;
RT   "VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic
RT   hypermutation, intraclonal heterogeneity, and a role for antigen
RT   selection.";
RL   Blood 88:3562-3568(1996).
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
RX   PubMed=9525742; DOI=10.1038/sj.onc.1201699;
RA   Crook T., Parker G.A., Rozycka M., Crossland S., Allday M.J.;
RT   "A transforming p53 mutant, which binds DNA, transactivates and
RT   induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.";
RL   Oncogene 16:1429-1441(1998).
RX   PubMed=9583678; DOI=10.1038/sj.onc.1201704;
RA   Brimmell M., Mendiola R., Mangion J., Packham G.;
RT   "BAX frameshift mutations in cell lines derived from human
RT   haemopoietic malignancies are associated with resistance to apoptosis
RT   and microsatellite instability.";
RL   Oncogene 16:1803-1812(1998).
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
RX   PubMed=9770427; DOI=10.1006/viro.1998.9363;
RA   Raisch K.P., Kushnaryov V.M., Grossberg S.E., Cashdollar L.W.;
RT   "Constitutive production of a murine retrovirus in the human
RT   B-lymphoblastoid cell line, DG-75.";
RL   Virology 250:135-139(1998).
RX   PubMed=11425244; DOI=10.1002/1522-2683(200105)22:9<1867::AID-ELPS1867>3.0.CO;2-7;
RA   Poirier F., Pontet M., Labas V., le Caer J.-P., Sghiouar-Imam N.,
RA   Raphael M., Caron M., Joubert-Caron R.;
RT   "Two-dimensional database of a Burkitt lymphoma cell line (DG 75)
RT   proteins: protein pattern changes following treatment with
RT   5'-azycytidine.";
RL   Electrophoresis 22:1867-1877(2001).
RX   PubMed=12706092; DOI=10.1016/S0042-6822(02)00074-0;
RA   Raisch K.P., Pizzato M., Sun H.-Y., Takeuchi Y., Cashdollar L.W.,
RA   Grossberg S.E.;
RT   "Molecular cloning, complete sequence, and biological characterization
RT   of a xenotropic murine leukemia virus constitutively released from the
RT   human B-lymphoblastoid cell line DG-75.";
RL   Virology 308:83-91(2003).
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).